Platelet Strategy Paper 2018-2022 - the Business Services ...
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Platelet Strategy Paper
2018-2022Contents
Page
1. Background 2-3
2. Current Position 3-4
3. Demand for Platelets 4
4. Factors Affecting Future Demand 5
5. Constraints/Pre Requisites /Relevant Factors 6-11
6. Options 11-12
7. Non-Financial Assessment 12-14
8. Financial Assessment 14
9. Findings/Conclusions 15
10. Projected issue figures for platelet components 16
for 2018/19 – 2020/21
Appendix 2 17-20
1Platelet Strategy Paper
1.0 Background
1.1 Physiological function and clinical application of platelets
Platelets are fragments of human blood which are involved in stopping bleeding or
preventing bleeding occurring in the first place.
The majority of platelet components are transfused to patients who have a low
platelet count as a result of treatment for cancer. The effect of chemotherapy is to
injure the bone marrow which recovers within thirty days but during this time the
patient is at risk of spontaneous haemorrhage.
Platelet components are also administered for other conditions associated with low
platelet count including vascular repair surgery, massive haemorrhage and liver
disease.
1.2 Platelet Production Methods
There are two sources of platelet components: apheresis component
donations and pooled platelets.
Apheresis is a medical procedure using a cell separator device and single or multiple
doses may be collected from the donor. There are a number of advantages for
apheresis component donations which include reduced donor exposure (an adult
therapeutic dose is donated by one donor whereas pooled platelets are
manufactured from four source whole blood donations), consistently high yield and
mitigation of transfusion related acute lung injury (TRALI). This is because male
donors are used or female donors who have been screened for antibodies which are
implicated in this serious adverse event associated with platelet transfusion.
Pooled platelets are obtained from four whole blood donations from accredited
donors (one completed donation with negative infectious diseases screening results
in the preceding twenty four months). A single buffy coat (platelet rich fraction) is
separated from a whole blood donation and four single buffy coats are pooled and
re-suspended in one of the donor plasmas which is specified male only.
1.3 Safety advisory committee for Blood Tissues Organs (SaBTO)
SaBTO is an expert committee advising UK government on policy matters related to
the safety of human blood, tissues and organs.
In 2009, SaBTO recommended that UK blood services, should as a minimum,
provide 80% of platelet issues as apheresis component donations and should move
as far as possible towards 100% apheresis platelets.
2In 2013, SaBTO concluded, following an expert sub group report, that the
requirement for 80% minimum apheresis platelet component donations should be
removed and platelet additive solution should be used for suspension of pooled
platelets. The decision of the target level proportion of apheresis level component
donations would be set by the individual blood services.
1.4 Purpose of the Platelet Strategy Document
The purpose of this paper is to determine the proportion of apheresis component and
pooled platelets to meet the anticipated demand for the four years 2018/19, 2019/20,
2020/21 and 2021/22 using best available evidence from current practice.
Information is provided by the Northern Ireland Transfusion Committee and
individual hospital transfusion committee reports.
2.0 Current Position
2.1 Northern Ireland Blood Transfusion Service
In the financial year 2017/18, the number of platelet components issued was 7,789.
The proportions issued for 2017/18 were 88% apheresis component donations and
12% pooled platelets.
The number of donors on the panel who have made a completed platelet donation
once in the last two years is 750. All female donors are screened for anti-HLA and
anti-neutrophil antibodies to mitigate TRALI risk.
The ABO groups of the donors who are currently active is:
ABO group Number of active donors
O 468
A 234
B 40
AB 8
There is high attrition of group B (38%) and group AB (58%) apheresis component
donations in the six months reported to 30 September 2017. Detailed data for
subsequent reference periods are not available.
Pooled platelets are manufactured as required and are linked to availability of
suitable whole blood donations. They comprise 12% of issues (1,182 for 2017/18).
Currently, the hospital services and component processing department prepare
single buffy coats from whole blood donations on the day of collection. Four buffy
coats with identical ABO groups are pooled on the day after the collection of whole
blood and after test results are transmitted to enable labelling of components. This is
known as day 0 production method. Group O and Group A pooled platelets are
manufactured routinely and group B and group AB may be manufactured in
response to a specific request. The pooled platelet is re-suspended in male only
plasma from one of the four contributing donations.
3NIBTS has a validated method for preparing single buffy coats on the day following
collection of whole blood which is described as day 1 production method. This
increases the potential number of pooled platelets which may be manufactured.
It is noted that the attrition rate for 2017/18 was 13% for apheresis component
donations and 15% for pooled platelets.
2.2 UK and Ireland Blood Transfusion Services
In the other UK Blood Services, the ratio of apheresis component donations to
pooled platelets varies between 70:30 and 50:50. The Irish Blood Transfusion
Service ratio is 80:20. Only male donors are eligible for apheresis collection and
group specific platelets are collected and manufactured using both methods in each
of the other Blood Services. Other UK and Ireland Blood Services collect and
manufacture ABO group specific platelets but manage donor panels so that attrition
of minor groups B and AB is minimised.
3.0 Demand for Platelets
3.1 Recent/Current demand
The number of issues of platelet components of NIBTS for the last seven financial
years is given in the table below:
Financial year Number of issues
2011/12 8,028
2012/13 8,189
2013/14 8,413
2014/15 8,737
2015/16 9,006
2016/17 8,629
2017/18 7,789
The last two reporting years have seen a reduction in demand from a high of 9,006
to the most recent result 7,789. Platelet demand is unpredictable and will relate to
case mix, programmes of treatment requiring intensive platelet support and health
service activity. Other relevant factors include the impact of clinical practice
guidelines which have the potential when implemented to reduce the increase in
demand or supress the clinical application of platelet component transfusion.
44.0 Factors affecting future demand
The factors affecting future demand are detailed in the table below with comment as
appropriate.
Factor Comment Likely impact on
demand
Population An ageing demographic is associated with Increase
an increase in platelet demand because of
increased diagnoses and more intensive
treatments of cancer.
HSC delivery Population screening for cancer- where Increase
of programmes for the diagnosis and
health care treatment of cancer are implemented and
priorities funded this will increase platelet demand.
The reason is chemotherapy and
radiotherapy regimes are associated with
bone marrow injury requiring intensive
platelet support for prevention of bleeding
until bone marrow recovery occurs.
Trauma The British Society for Haematology and Increase
European Trauma Group have (marginal)
recommended balanced component ratios
red cell component (1): plasma
component (1): platelet component (1) for
initial resuscitation of massively
haemorrhaging patients because of
penetrating trauma injuries.
Clinical NICE Guidance NG24 recommends Decrease
practice withdrawal of platelets for routine
guidelines prophylaxis of haemorrhage (prevention of
bleeding) in a number of defined
haematological conditions. This has the
potential to decrease demand. Some of
this decrease may have occurred but the
Northern Ireland Transfusion Committee
and individual hospital transfusion
committees predict further reduction in
platelet transfusion may occur.
Medical Clinical trials in relation to autologous stem Decrease
research cell transplantation are recommending
withdrawal and/or reduction of routine
platelet prescribing for prophylaxis of
haemorrhage. The trial of prophylactic
platelets (TOPPS study) British Journal of
Haematology and studies by Vandt et al
and others in Blood demonstrated non
inferior outcome for prophylaxis of
haemorrhage when platelet transfusions
were withheld versus standard approach in
prospective randomised controlled studies.
This has the potential to decrease demand.
54.1 Projected Demand
The demand for platelets remains unpredictable. Taking account of the factors listed
above and information sourced from the Northern Ireland Transfusion Committee,
Consultant Haematologists and transfusion laboratory managers, the projected
demand for each year until 2021/22 would appear to be 8,200 issues per annum.
This is also calculated from previous issues 2017/18 and issues April through August
2018 and projected for the year with an average result taken.
5.0 Constraints / Pre Requisites / Relevant Factors
5.1 Platelet Additive Solution
NIBTS has not implemented re-suspension of pooled platelets in additive solution at
the time of writing. This is a key SABTO recommendation which is linked to potential
patient safety. It is imperative that NIBTS implements platelet additive solution for
pooled platelets as a matter of urgency.
Recommendation 1: Implement platelet additive solution for pooled platelets.
5.2 Mass Casualty Planning
This item is not material for purposes of this paper.
5.3 Group Specific Platelets
The optimum platelet component for a patient is ABO identical. It is clinically
acceptable to cross groups and this may occur for groups B and AB for supply and
inventory management considerations.
Cross grouping is contingent on high titre testing as this identifies donations which
have a low titre of anti-A and anti-B (naturally occurring antibodies) which may be
transfused to non-group O recipients associated with a lower risk of transfusion
reaction.
NIBTS currently manufactures group specific platelet components. This is consistent
with other UK blood services and it is proposed that this practice continues.
There has been higher attrition of minor blood group B and AB components, this
should be monitored going forward and managed to ensure that attrition of these
groups is minimised.
It is also noted there is higher differential attrition rate of group O compared to group
A apheresis component donations (13% versus 5%). For this reason group A
donors should be selectively recruited and group O donors on the existing panel
managed in terms of donation interval so that attrition is minimised.
6Recommendation 2: Group A platelet apheresis donors should be preferentially
recruited and existing group O platelet apheresis donors actively managed for
donation
5.4 Gender of Platelet Donors
NIBTS currently manufactures pooled platelets prioritising male source whole blood
donations. The plasma for resuspension is mandated male only.
Other UK Blood Services manufacture pooled platelets from male and female
sourced whole blood donations but re-suspend in platelet additive solution.
Recommendation 3: Pooled platelets may be manufactured from male and female
whole blood donations. The plasma for resuspension is mandated male only.
Other UK blood services only permit platelet component donation from male donors.
This practice is adopted because of the perceived risk of TRALI from unscreened
female sourced plasma.
In relation to component donations, NIBTS has 170 female donors who have been
screened and confirmed negative for antibodies implicated in TRALI. This
consideration does not apply to male donors and there is a cost associated with
screening and repeat testing for a declared pregnancy event. Donors should be
profiled at enrolment to give a minimum double dose donation.
Recommendation 4: Both male and female donors are eligible for apheresis platelet
component donation.
5.5 Maximum Pooled Platelet Production
NIBTS is implementing Day 1 production method which involves overnight hold of
blood components, preparation of single buffy coats on the day after blood donation
and pooling on receipt of ABO group test results. The reason is compliance with
quality and regulatory standards for leucodepletion.
The projected yields from Day 1 production method across four days are modelled
and tabulated below.
Day 1 Production Method Modelled
7Factor Result Result/weekly production
(annual total) target *
Whole blood donations 45,000 865
Usable whole blood donations 42,750 822
(0.95)
Group O and Group A only (0.88) 37,620 723
Accredited whole blood 28,215 543
donations (0.75)
Accredited whole blood 23,215 446
donations streamed for FFP
manufacture (5,000)
Accredited whole blood 17,215 331
donations streamed for
cryoprecipitate manufacture
(6,000)
Accredited whole blood 15,215 293
donations streamed for
preparation of neonatal
components for exchange
transfusion and paedipack red
cell components (2,000)
Conversion factor (0.85 to 12,933 249
account for multiple of four factor)
Pooled platelets 3,233 62
Four production days (0.80) 2,586 50
* This is cited as an average figure but will respond flexibly and on a daily basis to
available stock and hospital blood bank requests.
8The projected yields from Day 1 production method across five days are
modelled and tabulated below.
Day 1 Production Method Modelled
Factor Result Result/weekly
(annual total) production target *
Whole blood donations 45,000 865
Usable whole blood 42,750 822
donations (0.95)
Group O and Group A only 37,620 723
(0.88)
Accredited whole blood 28,215 543
donations (0.75)
Conversion factor (0.85 to 23,983 461
account for multiple of four
factor)
Five production days 23,983 461
Accredited whole blood 18,983 365
donations streamed for FFP
manufacture (5,000)
Accredited whole blood 12,983 250
donations streamed for
cryoprecipitate manufacture
(6,000)
Accredited whole blood 10,983 211
donations streamed for
preparation of neonatal
components for exchange
transfusion and paedipack
red cell components (2,000)
Pooled platelets 2,745 53
* This is cited as an average figure but will respond flexibly and on a daily basis to
available stock and hospital blood bank requests.
The factors affecting manufacture of pooled platelets are detailed in the table below:
Whole blood collection numbers (45,000 based on 2017/18 collection yield)
Accredited donations (75%) based on 2017/18 performance results
Whole blood donations streamed for other products, FFP, cryoprecipitate,
exchange transfusion and paedipack red cell components.
Number of days for production
Conversion factor (0.85) single buffy coats prepared into finished pooled
platelet component. This reflects the constraints for pooling of identical ABO
group, RhD group and multiple of four.
95.6 Contingency and continuity of supply
Platelets are a short life blood component (licenced for 5 days, may be extended to 7
days when there is an automated bacterial detection system in place).
There is a variation in the number of daily issues from 11-57 with an average daily
issue or issuable stock index of 23.
Therefore, contingency and business continuity arrangements are critical because of
the unpredictable demand and inability to build stocks due to short shelf life.
The current contingency for a high proportion of apheresis component donations is
pooled platelets. This could be provided by increased apheresis component donation
but the continued manufacture of pooled platelets acts as a contingency in terms of
supply and in maintaining expertise in production method. Proposals to develop a
second apheresis facility have been put on hold because of reduction in demand for
platelets which has been more acute than expected or predicted.
5.7 Attrition Levels and Future Planning Assumptions
Apheresis component donations have a reported attrition rate of 12.7% for 2017/18.
The attrition results for 2018/19 to date are between 5.0% and 10.0%.
A reporting indicator recently introduced confirms attrition rates of 14.8% for pooled
platelets for 2017/18.
With active management of the donor panel and scheduling of donation intervals
other UK blood services report attrition rates of between 5.0-10.0% for both
apheresis platelet components and pooled platelets.
5.8 Yield – Proportion Single/ Double/ Triple
The current profile of donors attending NIBTS in 2017/18 is 15% giving a single
dose, 70% giving a double dose and 15% giving a triple dose. This translates to a
yield scale factor for 2017/18 of 1.92 which is explained by a higher relative attrition
of higher dose component donations. Yield scale factors of 2.0 and 2.1 are reported
by other UK blood services as single dose collections are only permitted by
exception for high value platelet phenotypes. The entry criterion for apheresis
platelet component donation is platelet count >280 X 109 /l.
Recommendation 5: Donors with a platelet count >280 X 10 9 /l are eligible for
apheresis platelet component donation.
105.9 High Titre Testing ( HT Testing )
Donors of blood Group O have anti-A and anti-B antibodies. When platelets of group
O are transfused to non-group O recipients there is transmission of incompatible
plasma anti- A or Anti-B or both. This may give rise to a haemolytic transfusion
reaction (destruction of red cells in the recipient). For this reason group O donations
are tested for the titre or level of anti-A and anti-B antibody. Where Anti-A or anti-B
are present at a dilution > 1:100 of plasma, platelets are reserved and labelled for
group O use only. It is permitted to cross group O platelets to non-group O
recipients where high titre testing is negative.
NHS Blood and Transplant (NHSBT) and Welsh Blood Service (WBS) apply high
titre testing to all pooled platelets and Scottish National Blood Transfusion Service
(SNBTS) apply to group O pooled platelets only. This is not currently the practice in
NIBTS and the guidelines for UK Blood Transfusion Services (2013) recommend
high titre testing of group O pooled platelets.
NIBTS should implement high titre testing for all pooled platelets which offers the
potential advantage of maximising cross group platelet transfusions and minimising
attrition.
Recommendation 6: Implement HT testing for pooled platelets.
6.0 Options
The following five options for proportions of apheresis component donations and
pooled platelets donations are considered:
Option 1. Do nothing (status quo)
This option reflects the current position which is 85% of issues are apheresis
component donations group specific and 15% of issues are pooled platelets.
Option 2. Do minimum
This option reflects the current position which is 85% of issues are apheresis
component donations group specific and 15% of issues are pooled platelets with the
implementation of platelet additive solution and HT testing.
Option 3. Maximise Apheresis Component Donations (100%)
This option reflects 100% provision by apheresis component donations.
Option 4. Maximise pooled platelet production (day 1) (4 days)
This option reflects the maximum pooled platelet production over four days which
results in 52.3% proportion pooled platelets with the implementation of platelet
additive solution and HT testing.
11Option 5. Maximise pooled platelet production (day 1) (5 days)
This option reflects maximum pooled platelet production over five days which results
in 74.8% proportion pooled platelets with the implementation of platelet additive
solution and HT testing. This option is excluded for operational reasons.
Option 6. Increase pooled platelet production (Day 1) (5 days) This option
reflects an increase in whole blood collection specifically to increase pooled platelet
production but would lead to a significant attrition of red cell components and for this
reason this option is not considered further.
7.0 Non-Financial Assessment
Assessment Criteria
The following evaluation criteria were used for assessment:
7.1 Patient Safety
Platelet components should exceed the minimum acceptable standard for patient
safety and relevant considerations are infectious diseases transmission (donor
exposure), TRALI (apheresis component donations have an advantage because of
testing and pooled platelets have a disadvantage because of non-implementation of
platelet additive solution and residual female source plasma not screened) and
haemolytic transfusion reactions due to plasma incompatibility (HT testing).
7.2 Regulatory Compliance
The Joint Professional Advisory Committee (JPAC) of the UK Blood Services agrees
standards and makes recommendations for transfusion practice. NIBTS should
comply with JPAC guidance and follow SABTO recommendations. Relevant factors
include platelet additive solution and HT testing of group O pooled platelets.
7.3 Operational Feasibility
Operational feasibility considerations relate to changes required to implement which
in the case of Day 1 production and increasing the proportion of pooled platelets
include overnight storage at ambient temperature with monitoring, increased storage
space, workflow process considerations of quality monitoring results performance.
7.4 Contingency
This reflects redundant capacity within the options so that if one production method
fails, a second method may be ramped up.
7.5 Continuity of supply
Demand for platelet components is unpredictable and is complicated further by its
short shelf life. There are also peaks and troughs in demand so continuity of supply
is considered and scored separately.
12The following evaluation criteria are considered:
Patient safety
Regulatory compliance
Operational feasibility
Contingency
Continuity of supply
The evaluation criteria are weighted 40:30:10:10:10
Evaluation Option 1 Option 2 Option Option
Criteria 3 4
Patient Safety 30 40 40 40
Regulatory 20 30 30 30
Compliance
Operational 10 5 5 5
feasibility
Contingency 10 10 0 10
Continuity of 10 10 5 5
Supply
Total 80 95 80 90
7.6 Assessment of each Option
Option one achieves reduced scores for patient safety and regulatory compliance
because of non-implementation of pooled platelet measures. Higher scores are
achieved for operational feasibility due to no change in current practice and
contingency and continuity of supply because of the potential to increase pooled
platelets.
Aggregate score = 80
Option two achieves maximum scores for patient safety and regulatory compliance
because of implementation of pooled platelet measures. A reduced score is
achieved for operational feasibility because of the requirement to implement
changes. Maximum scores are achieved for contingency and continuity of supply
because of redundant capacity and possibility of increasing pooled platelets supply.
Aggregate score = 95
Option three achieves maximum scores for patient safety and regulatory
compliance. There is a lower score for operational feasibility because of the
requirement to increase plateletpheresis donor panel. There is no score for
contingency because of lack of redundant capacity (there is no second apheresis
facility).
Aggregate score = 80
13Option four achieves maximum score for regulatory compliance and a reduced
score for patient safety because of residual female source plasma not screened. A
reduced score is achieved for operational feasibility due to operational impact of
implementation measures. Maximum score is achieved for contingency because of
redundant capacity and a reduced score for continuity of supply because of
increased reliance on pooled platelets.
Aggregate score = 90
7.7 Preferred option
Option Two This achieves the highest score (95) and implementation of minimum
change maximises patient safety and achieves regulatory compliance. Accordingly,
option 2 is recommended as the preferred option.
8.0 Financial Assessment
8.1 Cost of Options
The cost of each option is detailed in Appendix 2 and summarised below.
Option 2018/19 2019/20 2020/21 2021/22 Recurrent Difference from Do
£000 £000 £000 £000 £000 Nothing
£000
1 859 859 859 859 859 -
2 860 860 860 860 860 1
3 860 877 877 877 877 18
4 860 845 845 845 845 (14)
8.2 Costing assumptions
The following assumptions were used:
Costs are shown at 2018/19 pay and price levels
It is assumed that there is no change in staffing requirements with each option
Apheresis attrition is assumed to be 10%
8.3 Assessment of Options
The cost difference between Option 1 - Do Nothing and Option 2 - Do Minimum is
negligible. Consequently, there are no financial constraints or affordability
implications of the recommendation to introduce PAS and HT testing.
Option 3, move to 100% apheresis platelets is the highest cost option.
Options 4 maximises pooled platelet production and shows a small cost reduction.
Overall, there is no material or significant difference in cost between Do Nothing and
the other options.
9.0 Findings/Conclusions
14As noted in section 7.6 above, option 2 is the preferred option for the proportion of
apheresis component donations and pooled platelets. This achieves the highest
non-financial score; has minimum disruption to current operational practice and
provides contingency and continuity of platelet supply. The financial assessment
does not materially affect the outcome.
In addition to the preferred option for proportion of apheresis component donations
and pooled platelets, a number of other factors were considered and
recommendations made. These are detailed in the text above and summarised in
9.1 below.
9.1 Recommendations
1. Implement platelet additive solution for pooled platelets.
2. Group A platelet apheresis donors should be preferentially recruited and
existing group O platelet apheresis donors actively managed for donation
3. Pooled platelets may be manufactured from male and female whole blood
donations. The plasma for resuspension is mandated male only.
4. Both male and female donors are eligible for apheresis platelet component
donation.
5. Donors with a platelet count >280 X 109 /l are eligible for apheresis platelet
component donation.
6. Implement HT testing for pooled platelets.
10
Appendix 1
15Projected issues for platelet components for 2018/19 – 2021/22 and the
relative proportions of apheresis component donations and pooled
platelets
Financial Year 2018/19 2019/20 2020/21 2021/22
Number of Issues 8,200 8,200 8,200 8,200
Proportion apheresis component 85% 85% 80% 75%
donations
Proportion pooled platelets 15% 15% 20% 25%
Average number of issues monthly 683 683 683 683
Average number of issues weekly 159 159 159 159
Average number of group O (weekly) 83 83 83 83
Average number of group A (weekly) 57 57 57 57
Average number of group B (weekly) 15 15 15 15
Average number of group AB (weekly) 4 4 4 4
Average number of HT tests (weekly) 159 159 159 159
Average number of male donations 144 144 151 159
(weekly)
Average number of female donations 15 15 8 0
(weekly)
Percentage of single dose collections 15 15 10 5
Percentage of double dose collections 70 70 70 70
Percentage of triple dose collections 15 15 20 25
Appendix 2
16Option 1 : Do Nothing
2018/19 2019/20 2020/21 2021/22 Recurrent
Pay Costs
Nurse Band 6 83,404 83,404 83,404 83,404 83,404
Admin Band 3 24,630 24,630 24,630 24,630 24,630
DSA Band 3 87,721 87,721 87,721 87,721 87,721
BMS Band 7 25,717 25,717 25,717 25,717 25,717
BMS Band 6 58,107 58,107 58,107 58,107 58,107
BMS Band 4 107,344 107,344 107,344 107,344 107,344
MLA Band 2 209,709 209,709 209,709 209,709 209,709
- - - - -
Total Pay Costs 596,631 596,631 596,631 596,631 596,631
Non Pay
Platelet Sets 189,880 189,880 189,880 189,880 189,880
Sample Pouch 23,392 23,392 23,392 23,392 23,392
Storage Bags 1,429 1,429 1,429 1,429 1,429
Micro Test (Apheresis) 31,391 31,391 31,391 31,391 31,391
Pooling Storage Bags 6,710 6,710 6,710 6,710 6,710
SCD Wafers 9,600 9,600 9,600 9,600 9,600
PAS - - - - -
High Titre Testing - - - - -
Total Non Pay 262,401 262,401 262,401 262,401 262,401
Total 859,032 859,032 859,032 859,032 859,032
17Option 2 - Do Minmum
2018/19 2019/20 2020/21 2021/22 Recurrent
Pay Costs
Nurse Band 6 83,404 83,404 83,404 83,404 83,404
Admin Band 3 24,630 24,630 24,630 24,630 24,630
DSA Band 3 87,721 87,721 87,721 87,721 87,721
BMS Band 7 25,717 25,717 25,717 25,717 25,717
BMS Band 6 58,107 58,107 58,107 58,107 58,107
BMS Band 4 107,344 107,344 107,344 107,344 107,344
MLA Band 2 209,709 209,709 209,709 209,709 209,709
- - - - -
Total Pay Costs 596,631 596,631 596,631 596,631 596,631
Non Pay
Platelet Sets 189,880 189,880 189,880 189,880 189,880
Sample Pouch 23,392 23,392 23,392 23,392 23,392
Storage Bags 1,429 1,429 1,429 1,429 1,429
Micro Test (Apheresis) 31,391 31,391 31,391 31,391 31,391
Pooling Storage Bags 6,710 6,710 6,710 6,710 6,710
SCD Wafers 9,600 9,600 9,600 9,600 9,600
PAS 360 720 720 720 720
High Titre Testing 240 480 480 480 480
Total Non Pay 263,001 263,601 263,601 263,601 263,601
Total 859,632 860,232 860,232 860,232 860,232
18Option 3 - Maximise Apheresis Compnent Donation (100%)
2018/19 2019/20 2020/21 2021/22 Recurrent
Pay Costs
Nurse Band 6 83,404 83,404 83,404 83,404 83,404
Admin Band 3 24,630 24,630 24,630 24,630 24,630
DSA Band 3 87,721 87,721 87,721 87,721 87,721
BMS Band 7 25,717 25,717 25,717 25,717 25,717
BMS Band 6 58,107 58,107 58,107 58,107 58,107
BMS Band 4 107,344 107,344 107,344 107,344 107,344
MLA Band 2 209,709 209,709 209,709 209,709 209,709
- - - - -
- - - - -
Total Pay Costs 596,631 596,631 596,631 596,631 596,631
Non Pay
Platelet Sets 189,880 216,200 216,200 216,200 216,200
Sample Pouch 23,392 26,634 26,634 26,634 26,634
Storage Bags 1,429 1,627 1,627 1,627 1,627
Micro Test (Apheresis) 31,391 35,742 35,742 35,742 35,742
Pooling Storage Bags 6,710 - - - -
SCD Wafers 9,600 - - - -
PAS 360 - - - -
High Titre Testing 240 - - - -
Total Non Pay 263,001 280,203 280,203 280,203 280,203
Total 859,632 876,833 876,833 876,833 876,833
19Option 4 - Maximise Pooled Platelet Production (4days)
2018/19 2019/20 2020/21 2021/22 Recurrent
Pay Costs
Nurse Band 6 83,404 83,404 83,404 83,404 83,404
Admin Band 3 24,630 24,630 24,630 24,630 24,630
DSA Band 3 87,721 87,721 87,721 87,721 87,721
BMS Band 7 25,717 25,717 25,717 25,717 25,717
BMS Band 6 58,107 58,107 58,107 58,107 58,107
BMS Band 4 107,344 107,344 107,344 107,344 107,344
MLA Band 2 209,709 209,709 209,709 209,709 209,709
- - - - -
- - - - -
Total Pay Costs 596,631 596,631 596,631 596,631 596,631
Non Pay
Platelet Sets 189,880 160,505 160,505 160,505 160,505
Sample Pouch 23,392 19,773 19,773 19,773 19,773
Storage Bags 1,429 1,208 1,208 1,208 1,208
Micro Test (Apheresis) 31,391 26,535 26,535 26,535 26,535
Pooling Storage Bags 6,710 15,350 15,350 15,350 15,350
SCD Wafers 9,600 21,960 21,960 21,960 21,960
PAS 360 1,647 1,647 1,647 1,647
High Titre Testing 240 1,098 1,098 1,098 1,098
Total Non Pay 263,001 248,075 248,075 248,075 248,075
Total 859,632 844,706 844,706 844,706 844,706
Prepared by Dr Kieran Morris, 14 November 2018, with inputs from
Mr Glenn Bell, Mrs Alison Geddis, and Ms Angela Macauley.
20You can also read
